Innovation in Precision Therapies for CNS Diseases, Craig Chambliss, Co-Founder and CEO, Neurelis

Synopsis: In this episode of Biotech2050, host Alok Tayi engages in a profound conversation with Craig Chambliss, CEO and co-founder of Neurellis, delving into their strategic advancements in precision therapies for CNS diseases. Chambliss shares his journey, highlighting his finance and accounting background and pivotal roles in pharmaceutical companies like Bristol Myers Squibb and Alza Pharmaceuticals. His passion for impactful drug delivery technologies led to the launch of life-changing products, including an intranasal diazepam program for seizure emergencies, ultimately culminating in the founding of Neurellis in 2008. With the approval of their product Altoco in 2020, Neurellis addressed unmet needs in the epilepsy market, emphasizing the significance of a passionate team and a foundational product for successful clinical trials and market access. The conversation emphasizes the importance of precision therapies in the CNS space, collaboration for innovative solutions, and the potential of Neurellis' pipeline in addressing severe epileptic encephalopathies. Chambliss's insights into the strategic management of a biotech company, the utilization of platform technologies, and the evolving landscape of the biotech industry offer compelling takeaways for biotech executives seeking strategic insights. This episode provides a valuable opportunity to gain strategic insights into precision therapies for CNS diseases and the journey of a successful biotech company. Biography: Craig Chambliss’ 30-year tenure in the biopharma and drug delivery sectors has largely specialized in rare diseases of the central nervous system (CNS) and epilepsy. As the co-founder, CEO, and President of Neurelis, he has orchestrated the company's growth, securing over $300M in funding and guiding its evolution into a fully integrated organization, spanning from early-stage development to commercialization. Before his current role at Neurelis, Mr. Chambliss played a key part in reshaping NextWave Pharmaceuticals into a CNS-focused entity, serving as its Chief Business Officer. Under his leadership, NextWave secured $45M in Series C financing and was later acquired by Pfizer in a deal value exceeding $700M in 2012. Prior to NextWave, he also helped rebuild Questcor Pharmaceuticals as a CNS-focused organization, where he led commercial operations supporting the relaunch of Acthar® Gel for the treatment of a rare epilepsy disorder in pediatric patients. Mr. Chambliss's pharmaceutical journey began in sales at Bristol Myers Squibb and continued through various roles at Alza Pharmaceuticals and Elan Pharmaceuticals. In 2001, he helped launch Xcel Pharmaceuticals, a CNS startup focusing on epilepsy treatment, leading to a successful acquisition by Valeant Pharmaceuticals in 2005 for $280M. His academic foundation includes Bachelor of Science degrees in Finance and Accounting from Missouri State University.